XML 23 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
Collaborations (Details)
1 Months Ended 3 Months Ended 1 Months Ended 10 Months Ended 1 Months Ended 10 Months Ended 1 Months Ended 10 Months Ended 1 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 12 Months Ended 6 Months Ended 1 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended
Aug. 31, 2012
USD ($)
Mar. 31, 2013
USD ($)
Mar. 31, 2012
USD ($)
Mar. 31, 2013
Erbitux [Member]
USD ($)
Mar. 31, 2012
Erbitux [Member]
USD ($)
Mar. 31, 2013
Effient [Member]
USD ($)
Mar. 31, 2012
Effient [Member]
USD ($)
Mar. 31, 2013
Amylin [Member]
USD ($)
Mar. 31, 2012
Amylin [Member]
USD ($)
Mar. 31, 2013
Exenatide [Member]
USD ($)
Mar. 31, 2012
Exenatide [Member]
USD ($)
Mar. 31, 2013
Boerhringer Ingelheim (BI) [Member]
USD ($)
Mar. 31, 2012
Boerhringer Ingelheim (BI) [Member]
USD ($)
Mar. 31, 2011
Boerhringer Ingelheim (BI) [Member]
USD ($)
Nov. 30, 2011
Sales [Member]
Amylin [Member]
Oct. 31, 2011
Sales [Member]
Outside the United States [Member]
Exenatide [Member]
Aug. 31, 2012
Revenue Share [Member]
Amylin [Member]
USD ($)
Nov. 30, 2011
Revenue Share [Member]
Amylin [Member]
USD ($)
Nov. 30, 2011
Revenue Share [Member]
United States [Member]
Amylin [Member]
Nov. 30, 2011
Revenue Share [Member]
Outside the United States [Member]
Amylin [Member]
Oct. 31, 2011
Gross Margin Share [Member]
United States [Member]
Exenatide [Member]
Jun. 30, 2001
Profit and Development and Marketing Share [Member]
Effient [Member]
Dec. 31, 2009
Research and Development Exp [Member]
Baricitinib [Member]
Oct. 31, 2011
Research and Development and Marketing and Selling Expense [Member]
United States [Member]
Exenatide [Member]
Nov. 30, 2011
Milestone Payments, Development and Regulatory [Member]
Amylin [Member]
USD ($)
Mar. 31, 2013
Milestone Payments, Development and Regulatory [Member]
BI compounds [Member]
USD ($)
Mar. 31, 2013
Milestone Payments, Development and Regulatory [Member]
BI compounds [Member]
EUR (€)
Dec. 31, 2011
Milestone Payments, Development and Regulatory [Member]
BI compounds [Member]
USD ($)
Mar. 31, 2011
Milestone Payments, Development and Regulatory [Member]
LLY compounds [Member]
USD ($)
Mar. 31, 2011
Milestone Payments, Development and Regulatory [Member]
LLY optional compound [Member]
USD ($)
Dec. 31, 2009
Milestone Payments, Development and Regulatory [Member]
Baricitinib [Member]
USD ($)
Dec. 31, 2012
Milestone Payments, Development and Regulatory [Member]
Baricitinib [Member]
USD ($)
Dec. 31, 2010
Milestone Payments, Development and Regulatory [Member]
Baricitinib [Member]
USD ($)
Jun. 30, 2011
Milestone Payments, Sales-based [Member]
TPG-Axon [Member]
USD ($)
Dec. 31, 2009
Milestone Payments, Sales-based [Member]
Baricitinib [Member]
USD ($)
Jun. 30, 2011
Royalty Payments Expense [Member]
Solanezumab [Member]
Dec. 31, 2009
Royalty Payments Expense [Member]
Baricitinib [Member]
Jun. 30, 2011
Loan Commitment [Member]
Exenatide Once Weekly [Member]
USD ($)
Nov. 30, 2011
Upfront Payment [Member]
Amylin [Member]
USD ($)
Nov. 30, 2011
Secured Note [Member]
Amylin [Member]
Net product sales   $ 5,448,500,000 $ 5,413,800,000 $ 25,300,000 $ 34,000,000 $ 115,900,000 $ 115,800,000     $ 64,100,000 $ 48,500,000                                                          
Collaboration and other revenue   153,500,000 188,200,000 69,600,000 79,300,000         0 51,300,000 42,600,000 12,900,000                                                      
Revenue   5,602,000,000 5,602,000,000 94,900,000 113,300,000         64,100,000 99,800,000                                                          
Income related to transfer of exenatide rights   495,400,000 0         495,400,000 0                                                              
Research and development   1,348,100,000 1,151,500,000                                                                          
Collaborative Arrangement, Income Statement Classification and Amounts   45,200,000 46,800,000                                                                          
Collaborative Arrangement, Rights and Obligations, Terms                                 1,260,000,000 1,200,000,000             150,000,000 (92,200,000) (228,800,000) (478,700,000) 300,000,000 525,000,000 (515,000,000) (50,000,000) (49,000,000) (70,000,000) (150,000,000)     (165,000,000) 250,000,000  
Collaborative Arrangement, Rights and Obligations, Terms of Arrangement, Period                                                                       8 years        
Debt Instrument, Interest Rate, Stated Percentage                                                                               9.50%
Collaborative Arrangement, Rights and Obligations Percent                             15.00% 100.00%     65.00% 35.00% 50.00% 50.00% 30.00% 50.00%                         20.00%      
Proceeds from prepayment of revenue-sharing obligation 1,210,000,000                                                                              
Acquired in-process research and development                           388,000,000                                                    
Amortization of Intangible Assets   $ 146,100,000 $ 147,700,000